Increasing the Efficiency of Clinical Trials of Antimicrobials: The Scientific Basis of Substantial Evidence of Effectiveness of Drugs
Open Access
- 1 September 2007
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (Supplement) , S153-S162
- https://doi.org/10.1086/519253
Abstract
In the United States, drug sponsors must obtain approval from the US Food and Drug Administration before licensure and widespread clinical use of druKeywords
This publication has 21 references indexed in Scilit:
- Interpreting the Results of Clinical Trials of Antimicrobial AgentsPublished by Elsevier ,2010
- Issues Related to the Design and Interpretation of Clinical Trials of Salvage Therapy for Invasive Mold InfectionClinical Infectious Diseases, 2006
- Salvage Therapy Trials in Invasive Fungal Disease: Challenges and OpportunitiesClinical Infectious Diseases, 2006
- Microbiologic Surrogate End Points in Clinical Trials of Infectious Diseases: Example of Acute Otitis Media TrialsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Empirical Antifungal Therapy in Febrile Neutropenic Patients: Caution about Composite End Points and the Perils ofPValuesClinical Infectious Diseases, 2004
- Commentary: Hormone replacement therapy and coronary heart disease: four lessonsInternational Journal of Epidemiology, 2004
- Clinical trial of patulin in the common coldInternational Journal of Epidemiology, 2004
- Correlation between bacteriologic and clinical endpoints in trials of acute otitis mediaThe Pediatric Infectious Disease Journal, 2003
- The pros and cons of noninferiority trialsFundamental & Clinical Pharmacology, 2003
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996